BACKGROUND: Zika virus (ZIKV) has been linked to central nervous system malformations in fetuses. To characterize the spectrum of ZIKV disease in pregnant women and infants, we followed patients in Rio de Janeiro to describe clinical manifestations in mothers and repercussions of acute ZIKV infection in infants. METHODS: We enrolled pregnant women in whom a rash had developed within the previous 5 days and tested blood and urine specimens for ZIKV by reverse-transcriptase-polymerase-chain-reaction assays. We followed women prospectively to obtain data on pregnancy and infant outcomes. RESULTS: A total of 345 women were enrolled from September 2015 through May 2016; of these, 182 women (53%) tested positive for ZIKV in blood, urine, or both. The timing of acute ZIKV infection ranged from 6 to 39 weeks of gestation. Predominant maternal clinical features included a pruritic descending macular or maculopapular rash, arthralgias, conjunctival injection, and headache; 27% had fever (short-term and low-grade). By July 2016, a total of 134 ZIKV-affected pregnancies and 73 ZIKV-unaffected pregnancies had reached completion, with outcomes known for 125 ZIKV-affected and 61 ZIKV-unaffected pregnancies. Infection with chikungunya virus was identified in 42% of women without ZIKV infection versus 3% of women with ZIKV infection (P<0.001). Rates of fetal death were 7% in both groups; overall adverse outcomes were 46% among offspring of ZIKV-positive women versus 11.5% among offspring of ZIKV-negative women (P<0.001). Among 117 live infants born to 116 ZIKV-positive women, 42% were found to have grossly abnormal clinical or brain imaging findings or both, including 4 infants with microcephaly. Adverse outcomes were noted regardless of the trimester during which the women were infected with ZIKV (55% of pregnancies had adverse outcomes after maternal infection in the first trimester, 52% after infection in the second trimester, and 29% after infection in the third trimester). CONCLUSIONS: Despite mild clinical symptoms in the mother, ZIKV infection during pregnancy is deleterious to the fetus and is associated with fetal death, fetal growth restriction, and a spectrum of central nervous system abnormalities. (Funded by Ministério da Saúde do Brasil and others.).
BACKGROUND:Zika virus (ZIKV) has been linked to central nervous system malformations in fetuses. To characterize the spectrum of ZIKV disease in pregnant women and infants, we followed patients in Rio de Janeiro to describe clinical manifestations in mothers and repercussions of acute ZIKV infection in infants. METHODS: We enrolled pregnant women in whom a rash had developed within the previous 5 days and tested blood and urine specimens for ZIKV by reverse-transcriptase-polymerase-chain-reaction assays. We followed women prospectively to obtain data on pregnancy and infant outcomes. RESULTS: A total of 345 women were enrolled from September 2015 through May 2016; of these, 182 women (53%) tested positive for ZIKV in blood, urine, or both. The timing of acute ZIKV infection ranged from 6 to 39 weeks of gestation. Predominant maternal clinical features included a pruritic descending macular or maculopapular rash, arthralgias, conjunctival injection, and headache; 27% had fever (short-term and low-grade). By July 2016, a total of 134 ZIKV-affected pregnancies and 73 ZIKV-unaffected pregnancies had reached completion, with outcomes known for 125 ZIKV-affected and 61 ZIKV-unaffected pregnancies. Infection with chikungunya virus was identified in 42% of women without ZIKV infection versus 3% of women with ZIKV infection (P<0.001). Rates of fetal death were 7% in both groups; overall adverse outcomes were 46% among offspring of ZIKV-positive women versus 11.5% among offspring of ZIKV-negative women (P<0.001). Among 117 live infants born to 116 ZIKV-positive women, 42% were found to have grossly abnormal clinical or brain imaging findings or both, including 4 infants with microcephaly. Adverse outcomes were noted regardless of the trimester during which the women were infected with ZIKV (55% of pregnancies had adverse outcomes after maternal infection in the first trimester, 52% after infection in the second trimester, and 29% after infection in the third trimester). CONCLUSIONS: Despite mild clinical symptoms in the mother, ZIKV infection during pregnancy is deleterious to the fetus and is associated with fetal death, fetal growth restriction, and a spectrum of central nervous system abnormalities. (Funded by Ministério da Saúde do Brasil and others.).
Authors: Jernej Mlakar; Misa Korva; Nataša Tul; Mara Popović; Mateja Poljšak-Prijatelj; Jerica Mraz; Marko Kolenc; Katarina Resman Rus; Tina Vesnaver Vipotnik; Vesna Fabjan Vodušek; Alenka Vizjak; Jože Pižem; Miroslav Petrovec; Tatjana Avšič Županc Journal: N Engl J Med Date: 2016-02-10 Impact factor: 91.245
Authors: Guilherme A Calvet; Ana Maria B Filippis; Marcos Cesar L Mendonça; Patricia C Sequeira; Andre M Siqueira; Valdilea G Veloso; Rita M Nogueira; Patrícia Brasil Journal: J Clin Virol Date: 2015-11-23 Impact factor: 3.168
Authors: José Villar; Leila Cheikh Ismail; Cesar G Victora; Eric O Ohuma; Enrico Bertino; Doug G Altman; Ann Lambert; Aris T Papageorghiou; Maria Carvalho; Yasmin A Jaffer; Michael G Gravett; Manorama Purwar; Ihunnaya O Frederick; Alison J Noble; Ruyan Pang; Fernando C Barros; Cameron Chumlea; Zulfiqar A Bhutta; Stephen H Kennedy Journal: Lancet Date: 2014-09-06 Impact factor: 79.321
Authors: Gilberto A Santiago; Edgardo Vergne; Yashira Quiles; Joan Cosme; Jesus Vazquez; Juan F Medina; Freddy Medina; Candimar Colón; Harold Margolis; Jorge L Muñoz-Jordán Journal: PLoS Negl Trop Dis Date: 2013-07-11
Authors: Robert S Lanciotti; Olga L Kosoy; Janeen J Laven; Jason O Velez; Amy J Lambert; Alison J Johnson; Stephanie M Stanfield; Mark R Duffy Journal: Emerg Infect Dis Date: 2008-08 Impact factor: 6.883
Authors: Ai-Ris Y Collier; Erica N Borducchi; Abishek Chandrashekar; Edward Moseley; Lauren Peter; Nicholas S Teodoro; Joseph Nkolola; Peter Abbink; Dan H Barouch Journal: Am J Reprod Immunol Date: 2020-07-01 Impact factor: 3.886
Authors: Mathilde Guerbois; Ildefonso Fernandez-Salas; Sasha R Azar; Rogelio Danis-Lozano; Celia M Alpuche-Aranda; Grace Leal; Iliana R Garcia-Malo; Esteban E Diaz-Gonzalez; Mauricio Casas-Martinez; Shannan L Rossi; Samanta L Del Río-Galván; Rosa M Sanchez-Casas; Christopher M Roundy; Thomas G Wood; Steven G Widen; Nikos Vasilakis; Scott C Weaver Journal: J Infect Dis Date: 2016-07-19 Impact factor: 5.226
Authors: Shannon R Esswein; Harry B Gristick; Andrea Jurado; Avery Peace; Jennifer R Keeffe; Yu E Lee; Alisa V Voll; Mohsan Saeed; Michel C Nussenzweig; Charles M Rice; Davide F Robbiani; Margaret R MacDonald; Pamela J Bjorkman Journal: Proc Natl Acad Sci U S A Date: 2020-04-22 Impact factor: 11.205
Authors: Christie L Walker; Audrey A Merriam; Eric O Ohuma; Manjiri K Dighe; Michael Gale; Lakshmi Rajagopal; Aris T Papageorghiou; Cynthia Gyamfi-Bannerman; Kristina M Adams Waldorf Journal: Am J Obstet Gynecol Date: 2018-05-05 Impact factor: 8.661